Session Title: Quick Fire Free Paper Session 02
Session Date/Time: Thursday 26/09/2013 | 14:30-16:00
Paper Time: 15:00
Venue: Hall G1 (Level 2)
First Author: P.Freitas-da-Costa PORTUGAL
Co Author(s): J. Pinheiro-Costa M. Falc E. Brand ?. Carneiro
To evaluate the medium and long-term efficacy of anti-VEGF agents in the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV).
Study performed at Hospital São João (Oporto, Portugal), a tertiary wealth care center.
We performed a retrospective analysis of patients with mCNV treated with intravitreal anti-VEGF (bevacizumab and/or ranibizumab) for a minimum of 2 to a maximum of 5 years. All patients included in the study were treated according to the scheme of 1+PRN. The best-corrected visual acuity (BCVA, ETDRS charts) and central retinal thickness (CRT) were compared before and after treatment. The prognostic factors included in the multivariable linear regression analysis were age, baseline BCVA, membrane location and previous photodynamic therapy. The number of injections per year was also evaluated.
The results were analyzed at 2 years for 67 eyes, at 3 years for 52 eyes, at 4 years for 28 eyes and at 5 years for 13 eyes. Mean baseline BCVA and CRT were 44.3 ± 19.8 letters and 293.5 ± 123.9 μm, respectively. The mean BCVA change was significant at 2 years (+8.6 letters, p < 0.0001) and remained significantly stable in this profit until a period of 5 years (+9.0 at 3 years, p <0.0001; +9.8 and +9.6 at 4 and 5 years, respectively, p < 0.05). In multivariable regression analysis, the baseline BCVA was positively correlated with the final BCVA at 2 and 3 years. Mean CRT showed a significant decrease over time (-104.0 μm and -100.4 μm at 2 and 3 years, respectively, p <0.0001; -69.2 μm at 4 years, p = 0.01). The mean number of injections performed at first year was 5.2, being lower in subsequent years (2.2, 1.9, 1.9 and 1.4 in years 2, 3, 4 and 5 respectively, p <0.0001).
In this subgroup of patients with myopic CNV intravitreal therapy with anti-VEGF agents proved effective results over a 5 years period, with an sustained increase in the BCVA as well as a reduction of CRT.